S100B is increased in mood disorders and may be reduced by antidepressive 
treatment

Schroeter, Matthias L.; Abdul-Khaliq, H.; Diefenbacher, A.; Blasig, I. E.

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

S100B is increased in mood disorders and may be reduced by antidepressive treatment

MPS-Authors

/persons/resource/persons19981

Schroeter, Matthias L.
MPI of Cognitive Neuroscience (Leipzig, -2003), The Prior Institutes, MPI for Human Cognitive and Brain Sciences, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

schroeter_S100B.pdf
(Any fulltext), 95KB

Supplementary Material (public)

There is no public supplementary material available

Citation

Schroeter, M. L., Abdul-Khaliq, H., Diefenbacher, A., & Blasig, I. E. (2002). S100B is increased in mood disorders and may be reduced by antidepressive treatment. NeuroReport, 13(13), 1675-1678.

Cite as: https://hdl.handle.net/11858/00-001M-0000-0010-D6C0-A

Abstract

Previous studies have reported alterations of glial cells and particularly astrocytes in mood disorders. Therefore, serum concentration of the astrocytic marker S100B was ascertained with an immunoluminometric assay in 20 patients with mood disorder and 12 healthy age-matched controls. Serum S100B was elevated in major depression (median after admission 410 ng/l, at discharge < 100 ng/l) and mania (130, 160 ng/l), when compared with controls (< 100 ng/l; rho< 0.01). Antidepressive treatment reduced S100B in conjunction with severity of depressive symptoms ( rho< 0.01). The severity of depression (Hamilton Depression Rating Scale) was positively correlated with S100B (r(s) = 0.51, rho< 0.005). Elevated serum S100B during depressive and manic episodes of mood disorders may indicate alterations of astrocytes, which are reversed by antidepressive treatment.